Skip to content
Screener

Relay Therapeutics, Inc. RLAY Q1 2025 earnings

Reported May 5, 2025 · After market close

Revenue$7.7MBeat by $3.9M
EPS-$0.46Beat by $0.04
Revenue estimate$3.8M
EPS estimate-$0.50

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.6M
EPS estimate-$0.40

Financials

Q1 2025

Income statement

See full
Revenue$7.7M-23.3%
Operating income-$84.9M+6.1%
Net income-$77.1M+5.3%
EPS (diluted)-$0.46+25.8%

Balance sheet

See full
Cash & equivalents$93.5M-38.8%
Total debt$47.2M-9.8%
Total equity$721.1M-3.3%
Total assets$799.4M-5.0%

Cash flow

See full
Operating cash flow-$73.2M-45.5%
CapEx$384.0K-78.4%
Free cash flow-$73.6M-41.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$444.15M-56.3%
Enterprise value$397.76M-56.6%
P/S57.8×+29.0×

Profitability

See full
Operating margin-4,778.9%-6,575pp
Net margin-4,341.5%-5,974pp
FCF margin-3,550.1%-5,053pp

Returns & leverage

See full
Return on equity-45.5%+6.5pp
Debt / equity0.1×0.0×
Current ratio20×-0.8×

FAQ

When did Relay Therapeutics, Inc. report Q1 2025 earnings?
Relay Therapeutics, Inc. (RLAY) reported Q1 2025 earnings on May 5, 2025 after market close.
What were Relay Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Relay Therapeutics, Inc. reported revenue of $7.7M and eps of $-0.46 for Q1 2025.
Did Relay Therapeutics, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $3.8M by $3.9M. EPS beat the consensus estimate of $-0.50 by $0.04.
How did Relay Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 23.3% from $10.0M a year earlier and eps grew 25.8% from $-0.62.
Where can I find Relay Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-063539) and the 10-Q periodic report (0000950170-25-063553) directly on SEC EDGAR. The filing index links above go to sec.gov.